• Merck raised its 2026 adjusted earnings forecast to $2.77-$2.82 a share from $2.66-$2.76.
• Revenue guidance narrowed to $66.8 billion-$67.3 billion from $66.3 billion-$67.3 billion, implying growth of 3%-4%.
• The expected tax rate fell to 32%-33% from 35%-36%, while operating expense guidance increased to $42.4 billion-$42.9 billion.
• The outlook includes a $400 million SciBrunch licensing charge, reducing expected earnings by $0.12 a share.
• Third-quarter sales benefited from roughly $550 million in favorable purchase timing; KEYTRUDA and WINREVAIR benefits should fully reverse in the fourth quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.